FMP
Shattuck Labs, Inc.
STTK
NASDAQ
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
1.15 USD
0.11 (9.57%)
About
ceo
Dr. Taylor H. Schreiber M.D., Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.shattucklabs.comexchange
NASDAQ
Description
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
CIK
0001680367
ISIN
US82024L1035
CUSIP
82024L103
Address
500 West 5th Street
Phone
512 900 4690
Country
US
Employee
75
IPO Date
Oct 9, 2020
Key Executives
